EU | pharmaphorum

EU

News

Pfizer’s ulcerative colitis drug Velsipity gets EU okay

The European Commission has approved Pfizer’s S1P receptor modulator Velsipity as a treatment for ulcerative colitis (UC), raising the pressure on Bristol-Myers Squibb’s f

News

Let’s Talk Prostate Cancer calls for action by MEPs

An organisation representing the interests of patients with prostate cancer has published a manifesto ahead of the EU elections next year, calling for more screening for t

News

Blow to Moderna as EU nixes mRNA vaccine patent

The European Patent Office has said it has invalidated a patent held by Moderna on mRNA-based COVID-19 vaccines, the latest development in an increasingly acrimonious disp

News

EFPIA warns EU reforms will hamstring pharma R&D

A trade organisation representing European pharmaceutical companies warned today that the European Commission’s proposed reforms to pharma legislation could result in the

News

Ipsen to refile Alagille drug after EU blocks orphan status

Ipsen has said that it plans to file a new marketing application for its treatment for itch in Alagille syndrome (ALGS), Bylvay, after failing to persuade an EMA committee

News

EU has its first RoActemra biosimilar, from Fresenius Kabi

The European Commission has approved the first biosimilar version of Actemra/RoActemra, Roche’s $3 billion blockbuster, from German drugmaker Fresenius Kabi.

Pfizer’s ulcerative colitis drug Velsipity gets EU okay

Let’s Talk Prostate Cancer calls for action by MEPs

Blow to Moderna as EU nixes mRNA vaccine patent

EFPIA warns EU reforms will hamstring pharma R&D

Ipsen to refile Alagille drug after EU blocks orphan status

EU has its first RoActemra biosimilar, from Fresenius Kabi

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

EU

Editor's Picks